These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22446059)

  • 41. Modification of levodopa responses by deprenyl (selegiline): an electrophysiological and behavioral study in the rat relevant to Parkinson's disease.
    Mercuri NB; Scarponi M; Federici M; Bonci A; Siniscalchi A; Bernardi G
    Ann Neurol; 1998 May; 43(5):613-7. PubMed ID: 9585355
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Compromised circadian function in Parkinson's disease: enucleation augments disease severity in the unilateral model.
    Willis GL; Kelly AM; Kennedy GA
    Behav Brain Res; 2008 Nov; 193(1):37-47. PubMed ID: 18547659
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment with phosphotidylglycerol-based nanoparticles prevents motor deficits induced by proteasome inhibition: implications for Parkinson's disease.
    Fitzgerald P; Mandel A; Bolton AE; Sullivan AM; Nolan Y
    Behav Brain Res; 2008 Dec; 195(2):271-4. PubMed ID: 18817814
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?
    Lane EL; Cheetham SC; Jenner P
    Exp Neurol; 2006 Feb; 197(2):284-90. PubMed ID: 16005456
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of Hibiscus rosa sinensis on reserpine-induced neurobehavioral and biochemical alterations in rats.
    Nade VS; Dwivedi S; Kawale LA; Upasani CD; Yadav AV
    Indian J Exp Biol; 2009 Jul; 47(7):559-63. PubMed ID: 19761039
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P; Marsden CD
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dopamine cell degeneration induced by intraventricular administration of 6-hydroxydopamine in the rat: similarities with cell loss in parkinson's disease.
    Rodríguez M; Barroso-Chinea P; Abdala P; Obeso J; González-Hernández T
    Exp Neurol; 2001 May; 169(1):163-81. PubMed ID: 11312569
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Motor impairments after methamphetamine-induced neurotoxicity in the rat.
    Walsh SL; Wagner GC
    J Pharmacol Exp Ther; 1992 Nov; 263(2):617-26. PubMed ID: 1432692
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Korean ginseng extract attenuates reserpine-induced orofacial dyskinesia and improves cognitive dysfunction in rats.
    Sanghavi CR; Barhate SA; Mahajan MS; Mohan M; Kasture SB
    Nat Prod Res; 2011 Apr; 25(7):704-15. PubMed ID: 20628966
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tiagabine, a GABA uptake inhibitor, attenuates 3-nitropropionic acid-induced alterations in various behavioral and biochemical parameters in rats.
    Dhir A; Akula KK; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):835-43. PubMed ID: 18234412
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intrastriatal injection of sonic hedgehog reduces behavioral impairment in a rat model of Parkinson's disease.
    Tsuboi K; Shults CW
    Exp Neurol; 2002 Jan; 173(1):95-104. PubMed ID: 11771942
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations.
    Ferro MM; Bellissimo MI; Anselmo-Franci JA; Angellucci ME; Canteras NS; Da Cunha C
    J Neurosci Methods; 2005 Oct; 148(1):78-87. PubMed ID: 15939479
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nociception alterations precede motor symptoms in a progressive model of parkinsonism induced by reserpine in middle-aged rats.
    Cintra RR; Lins LCRF; Medeiros KAAL; Souza MF; Gois AM; Bispo JMM; Melo MS; Leal PC; Meurer YSR; Ribeiro AM; Silva RH; Marchioro M; Santos JR
    Brain Res Bull; 2021 Jun; 171():1-9. PubMed ID: 33675933
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interferon-gamma deficiency modifies the motor and co-morbid behavioral pathology and neurochemical changes provoked by the pesticide paraquat.
    Litteljohn D; Mangano E; Shukla N; Hayley S
    Neuroscience; 2009 Dec; 164(4):1894-906. PubMed ID: 19782123
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats.
    Pinna A; Fenu S; Morelli M
    Synapse; 2001 Mar; 39(3):233-8. PubMed ID: 11284438
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats.
    Peres FF; Levin R; Suiama MA; Diana MC; Gouvêa DA; Almeida V; Santos CM; Lungato L; Zuardi AW; Hallak JE; Crippa JA; Vânia D; Silva RH; Abílio VC
    Front Pharmacol; 2016; 7():343. PubMed ID: 27733830
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Repeated treatment with a low dose of reserpine as a progressive model of Parkinson's dementia.
    Ikram H; Haleem DJ
    Pak J Pharm Sci; 2019 Mar; 32(2):555-562. PubMed ID: 31081766
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterization of long-term motor deficits in the 6-OHDA model of Parkinson's disease in the common marmoset.
    Santana M; Palmér T; Simplício H; Fuentes R; Petersson P
    Behav Brain Res; 2015 Sep; 290():90-101. PubMed ID: 25934488
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of the face validity of reserpine administration as an animal model of depression--Parkinson's disease association.
    Skalisz LL; Beijamini V; Joca SL; Vital MA; Da Cunha C; Andreatini R
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Jun; 26(5):879-83. PubMed ID: 12369260
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Testosterone propionate improves motor alterations and dopaminergic damage in the reserpine-induced progressive model of Parkinson's disease.
    Bispo JMM; Melo JEC; Gois AM; Medeiros KAAL; Silva RS; Leal PC; Franco HS; Souza MF; Lins LCRF; Ribeiro AM; Silva RH; Santos JR
    Brain Res Bull; 2022 Sep; 187():162-168. PubMed ID: 35781030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.